CKPT vs. LPTX, ENTA, IMMP, EBS, FHTX, ACRV, XBIT, DSGN, RANI, and QURE
Should you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include Leap Therapeutics (LPTX), Enanta Pharmaceuticals (ENTA), Immutep (IMMP), Emergent BioSolutions (EBS), Foghorn Therapeutics (FHTX), Acrivon Therapeutics (ACRV), XBiotech (XBIT), Design Therapeutics (DSGN), Rani Therapeutics (RANI), and uniQure (QURE). These companies are all part of the "pharmaceutical preparations" industry.
Checkpoint Therapeutics (NASDAQ:CKPT) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.
Checkpoint Therapeutics currently has a consensus price target of $22.60, indicating a potential upside of 1,089.47%. Leap Therapeutics has a consensus price target of $11.00, indicating a potential upside of 352.67%. Given Checkpoint Therapeutics' higher probable upside, equities research analysts plainly believe Checkpoint Therapeutics is more favorable than Leap Therapeutics.
In the previous week, Checkpoint Therapeutics had 9 more articles in the media than Leap Therapeutics. MarketBeat recorded 10 mentions for Checkpoint Therapeutics and 1 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.19 beat Checkpoint Therapeutics' score of 0.13 indicating that Leap Therapeutics is being referred to more favorably in the news media.
Checkpoint Therapeutics has higher earnings, but lower revenue than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.
Leap Therapeutics has a net margin of 0.00% compared to Checkpoint Therapeutics' net margin of -50,336.89%. Checkpoint Therapeutics' return on equity of 0.00% beat Leap Therapeutics' return on equity.
22.0% of Checkpoint Therapeutics shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 2.1% of Checkpoint Therapeutics shares are owned by company insiders. Comparatively, 11.3% of Leap Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Checkpoint Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Leap Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Leap Therapeutics received 119 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. Likewise, 68.72% of users gave Leap Therapeutics an outperform vote while only 66.28% of users gave Checkpoint Therapeutics an outperform vote.
Summary
Leap Therapeutics beats Checkpoint Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Checkpoint Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CKPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Checkpoint Therapeutics Competitors List
Related Companies and Tools
